Bristol-Myers says hepatitis C drug combination succeeds in study

Bristol-Myers Squibb Co said its experimental drug cured hepatitis C in over 90 percent of patients in combination with Gilead Sciences Inc’s Sovaldi and a commonly prescribed drug, ribavirin, in a late-stage study. Data presented at the International Liver Congress on Saturday showed that the combination cured 94 percent of…

Read More